Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Parenteral Nutrition

10

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

4

US Previously Marketed

4

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

cell proliferation

4

Fatty acid desaturase 1

2

Fatty acid desaturase 2

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

10

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

4

1957

4

1994

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

Curative

6

Palliative

4

Preventing

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Rollett, A.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

10

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

10

FDA UNII

10

PUBCHEM

10

EPA CompTox

8

ECHA (EC/EINECS)

7

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 10 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

FERRIC OXYHYDROXIDE

87PZU03K0K

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Chronic kidney disease

Parenteral Nutrition

Iron deficiency

Iron compound. Used as a styptic and astringent.

LINOLEIC ACID

9KJL21T0QJ

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

cell proliferation

Conditions:

Multiple sclerosis

Parenteral Nutrition

Linoleic acid is a naturally occurring omega-6 essential fatty acid, present in a variety of foods, including the oils. Linoleic acid is a precursor for arachidonic acid biosynthesis; on the first enzymatic step of the pathway involves delta-6-desatu...

rase, which converts linoleic acid to gamma-lenolenic acid. Linoleic acid has beneficial effects on human skin and hair. Replacement of saturated fat with linoleic acid is advocated to improve serum lipoprotein profiles and reduce the risk of coronary artery disease. Linoleic acid was tested in clinical trilas as a possible remedy against multiple sclerosis.

SODIUM LINOLENATE

I5OYY436YI

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1994

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Fatty acid desaturase 2

Fatty acid desaturase 1

Conditions:

Parenteral Nutrition

Alpha-linolenic acid (ALA), an 18-carbon omega-3 essential fatty acid, is the precursor of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA cannot be synthesized by humans and therefore must be entirely acquired from exogenous sources....

Evidence for the essentiality of ALA was first provided by a study showing that ALA supplementation reversed the abnormal neurologic signs observed in a 6-year-old girl who suffered from sensory loss and visual complications. Most of the ALA is catabolized via beta-oxidation for energy generation, and a small proportion of it undergoes conversion to produce another two potent members of omega-3 PUFA family: EPA and DHA. Delta 6 desaturase (D6D) enzyme is responsible the conversion of ALA to DHA. Although not conclusive, it was suggested, that the benefits associated with ALA seem to stem mainly from EPA and DHA, and as major consequence of ALA deficiency it appears that EPA and DHA are not adequately produced.

FERRIC AMMONIUM CHLORIDE

3AQ7LKR09F

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Chronic kidney disease

Parenteral Nutrition

Iron deficiency

Iron compound. Used as a styptic and astringent.

FERRIC CHLORIDE DIHYDRATE

Y048945596

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Chronic kidney disease

Parenteral Nutrition

Iron deficiency

Iron compound. Used as a styptic and astringent.

FERRIC BROMIDE

9RDO128EH7

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Chronic kidney disease

Parenteral Nutrition

Iron deficiency

Iron compound. Used as a styptic and astringent.

LINOLELAIDIC ACID

7552P0K6PN

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

cell proliferation

Conditions:

Multiple sclerosis

Parenteral Nutrition

Linoleic acid is a naturally occurring omega-6 essential fatty acid, present in a variety of foods, including the oils. Linoleic acid is a precursor for arachidonic acid biosynthesis; on the first enzymatic step of the pathway involves delta-6-desatu...

rase, which converts linoleic acid to gamma-lenolenic acid. Linoleic acid has beneficial effects on human skin and hair. Replacement of saturated fat with linoleic acid is advocated to improve serum lipoprotein profiles and reduce the risk of coronary artery disease. Linoleic acid was tested in clinical trilas as a possible remedy against multiple sclerosis.

AMMONIUM LINOLEATE

H9ODY63839

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

cell proliferation

Conditions:

Multiple sclerosis

Parenteral Nutrition

Linoleic acid is a naturally occurring omega-6 essential fatty acid, present in a variety of foods, including the oils. Linoleic acid is a precursor for arachidonic acid biosynthesis; on the first enzymatic step of the pathway involves delta-6-desatu...

rase, which converts linoleic acid to gamma-lenolenic acid. Linoleic acid has beneficial effects on human skin and hair. Replacement of saturated fat with linoleic acid is advocated to improve serum lipoprotein profiles and reduce the risk of coronary artery disease. Linoleic acid was tested in clinical trilas as a possible remedy against multiple sclerosis.

SODIUM LINOLEATE

872C9A1W9I

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

cell proliferation

Conditions:

Multiple sclerosis

Parenteral Nutrition

Linoleic acid is a naturally occurring omega-6 essential fatty acid, present in a variety of foods, including the oils. Linoleic acid is a precursor for arachidonic acid biosynthesis; on the first enzymatic step of the pathway involves delta-6-desatu...

rase, which converts linoleic acid to gamma-lenolenic acid. Linoleic acid has beneficial effects on human skin and hair. Replacement of saturated fat with linoleic acid is advocated to improve serum lipoprotein profiles and reduce the risk of coronary artery disease. Linoleic acid was tested in clinical trilas as a possible remedy against multiple sclerosis.

LINOLENIC ACID

0RBV727H71

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1994

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Fatty acid desaturase 2

Fatty acid desaturase 1

Conditions:

Parenteral Nutrition

Alpha-linolenic acid (ALA), an 18-carbon omega-3 essential fatty acid, is the precursor of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA cannot be synthesized by humans and therefore must be entirely acquired from exogenous sources....

Evidence for the essentiality of ALA was first provided by a study showing that ALA supplementation reversed the abnormal neurologic signs observed in a 6-year-old girl who suffered from sensory loss and visual complications. Most of the ALA is catabolized via beta-oxidation for energy generation, and a small proportion of it undergoes conversion to produce another two potent members of omega-3 PUFA family: EPA and DHA. Delta 6 desaturase (D6D) enzyme is responsible the conversion of ALA to DHA. Although not conclusive, it was suggested, that the benefits associated with ALA seem to stem mainly from EPA and DHA, and as major consequence of ALA deficiency it appears that EPA and DHA are not adequately produced.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1